37 results about "Metabolic derangement" patented technology

Compounds of formula I which act as amylin agonists with respect to certain desired amylin activities and as calcitonin agonists with respect to certain desired calcitonin activities are provided. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including, but not limited to diabetes mellitus, including Type I diabetes and Type II diabetes. The present invention also relates to methods of treating Type I diabetes, treating Type II diabetes and to methods of beneficially regulating gastrointestinal motility comprising administration of a therapeutically effective among of one of the compounds. Also provided are pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier.

Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

The invention provides a medicine structurally containing a liver-targeting specific ligand and a thyroxine receptor agonist. The liver-targeting specific ligand and the thyroxine receptor agonist areconnected by branched chains, connectors and connecting chains to form a novel medicine structure. Thyroxine receptors (TRs) are divided into two subtypes, namely TR-alpha and TR-beta, wherein the TR-beta is mainly expressed in the liver, and the TR-alpha is mainly expressed in the heart, the nervous system and the like. In some embodiments, the medicine provided by the invention is expected to have a liver-targeting effect and can specifically bring the thyroxine receptor agonist into the liver so as to prevent the thyroxine receptor agonist from entering the heart and other tissues, so thatside effects triggered by the effect of the thyroxine receptor agonist on the other tissues can be avoided and the therapeutic effect of the medicine on treatment of lipid metabolism disorders and related complications is maintained.

Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.

Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

Intrauterine Fetal Growth Restriction (IUGR) is a very important clinical problem for which no satisfactory treatment is available so far. The current invention of intravenous (IV) hypertonic glucose supplementation to the mother to improve the glucose transfer to the fetus at the intervillous space by improved facilitated diffusion can be a safe and easy way of treating this problem, as the improved fetal blood glucose can lead to fetal lipogenesis that can conserve the fetal O2 (oxygen) utilization and also relieve the associated metabolic derangements of fetal hypoxia, hypercapnia, and acidosis, apart from replenishing the oxidized coenzymes needed for the carbohydrate metabolism. The use of trans-amniotic fetal feeding studied by animal experiments can be difficult in humans, because of the danger of infection, which can be overcome by the use of implantable ports with a sterile patch technique.

The present invention discloses a use of bergenin in preparation of drugs for treatment of diabetes, and belongs to the field of the pharmacological use of the bergenin. The results of animal experiments show that: with the bergenin, the model forming rate of type 2 diabetes rats can be significantly reduced, the occurrence and the development of insulin resistance can be prevented, the insulin resistance degree of the rats can be significantly reduced, and the insulin sensitivity of the type 2 diabetes rats can be effectively improved. In addition, the results provided by the present invention further show that: with the bergenin, the triglyceride content and the total cholesterol content in blood serum can be significantly reduced, and the lipid metabolism disorder of the type 2 diabetes rats can be effectively improved. Therefore, the results show that the bergenin can be used for preparing into the drugs for the treatment of the diabetes and the blood lipid reducing drugs.

The invention discloses steroid saponin compounds and a preparation method and application thereof. The preparation method comprises the steps of: mixing polygonatum odoratum with an aqueous solutionof ethanol for extraction, performing filtration and concentration by using an ultra filtration membrane and nanofiltration membrane device, then performing adsorption by using a macroporous resin column, performing elution with an aqueous solution of ethanol, performing concentration and recycling of ethanol, and performing freeze drying or spray drying to obtain steroid saponin extract; separating the steroid saponin extract by using low-and-medium pressure liquid chromatography with an OSD column, performing gradient elution by using a methanol aqueous solution with a volume concentration of 10-100%, and performing purification by using a preparative RP-HPLC to obtain the eight steroid saponin compounds. The steroid saponin compounds can be applied to prepare drugs for treating, improving and / or preventing metabolic syndromes, metabolic diseases, metabolic disorder and liver cancers of sugar or fat, food functional additives or healthy food, and the preparation method has simple operation and is easy to industrialize and popularize.

The current invention relates to the use of a physiologically acceptable organic and / or inorganic vanadium compound or complex, such as for example bis(maltolato)oxovanadium (BMOV) in the prevention or amelioration of stress-induced metabolic derangement in a subject. More in particular, the invention relates to a physiologically acceptable organic and / or inorganic vanadium compound or complex foruse in the amelioration of hyperglycemia in a subject suffering from stress such as elicited by a trauma, wherein the physiologically acceptable organic and / or inorganic vanadium compound or complexis administered to said subject before the trauma is inflicted to the subject. Furthermore, the invention relates to a physiologically acceptable organic and / or inorganic vanadium compound or complexfor use in the prevention of hyperglycemia in a subject having a trauma, wherein the physiologically acceptable organic and / or inorganic vanadium compound or complex is administered to said subject before the subject has the trauma. In one embodiment a physiologically acceptable organic and / or inorganic vanadium compound or complex is administered to a human subject 2 to 24 hours before said humansubject is subjected to surgery, for the prevention or amelioration of hyperglycemia elicited by a trauma related to the surgery. It is part of the invention that the physiologically acceptable organic and / or inorganic vanadium compound or complex are a source of vanadyl or vanadate in a patient to whom such compound or complex is administered.

The invention is directed to methods for treating disorders of amino acid metabolism, in particular, phenylketonuria (PKU). Such methods utilize novel compositions including Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) alone or in combination with other agents or treatment modalities.

The invention discloses a novel purpose of pteris multifida poir general flavone in preparation of medicine for treating hyperlipemia and atherosclerosis. The lipid-lowering and anti-atherosclerosis effects are studied through a rat lipid metabolism disturbance model and an atherosclerosis model; study results prove that the pteris multifida poir general flavone can reduce the contents of TG, CHO and LDL-C in the rat blood serum; the H / L ratio is increased; the atherosclerotic plaque length and area can be reduced; good lipid-lowering and anti-atherosclerosis effects are achieved; the pteris multifida poir general flavone can be prepared into medicine applied to the aspect.